News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE)'s Spiriva May Raise Risk of Early Death


6/15/2011 8:06:23 AM

Boehringer Ingelheim GmbH and Pfizer Inc. (PFE)’s Spiriva mist inhaler for chronic lung disease may raise the risk of an early death, a review of five studies found. The use of Spiriva administered in mist form was associated with a 52 percent increase in the risk of mortality, compared with patients given only a placebo, according to the review published today in the British Medical Journal. The analysis included five clinical trials involving more than 6,500 patients.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES